13029-74-8

Basic information

• Product Name: {[(4-METHOXYPHENYL)SULFONYL]AMINO}ACETIC ACID
• Synonyms: 2-(4-MethoxyphenylsulfonaMido)acetic acid
• CAS NO: 13029-74-8
• Molecular Formula: C₉H₁₁NO₅S
• Molecular Weight: 245.26
• Mol File: 13029-74-8.mol
• Article Data: 13

Chemical Properties

• Melting Point: 129 °C
• Boiling Point: 456.7°Cat760mmHg
• Flash Point: 230°C
• Appearance: /
• Density: 1.4g/cm³
• Vapor Pressure: 3.93E-09mmHg at 25°C
• PKA: 3.37±0.10(Predicted)
• CAS DataBase Reference: {[(4-METHOXYPHENYL)SULFONYL]AMINO}ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: {[(4-METHOXYPHENYL)SULFONYL]AMINO}ACETIC ACID(13029-74-8)
• EPA Substance Registry System: {[(4-METHOXYPHENYL)SULFONYL]AMINO}ACETIC ACID(13029-74-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 13029-74-8(Hazardous Substances Data)

Usage

General Description

{[(4-METHOXYPHENYL)SULFONYL]AMINO}ACETIC ACID, also known as Mefenamic acid, is a medication used to relieve moderate-to-severe pain, particularly menstrual pain. It works by reducing inflammation and blocking the production of certain substances in the body that cause pain and inflammation. Mefenamic acid belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs) and works by inhibiting the action of cyclooxygenase, which is an enzyme involved in the production of prostaglandins. This medication is available in oral form and should be taken with food or milk to reduce the risk of stomach irritation. Common side effects of mefenamic acid include stomach upset, nausea, vomiting, diarrhea, and dizziness. It should be used with caution in individuals with a history of heart disease, high blood pressure, or stomach ulcers.

InChI:InChI=1/C9H11NO5S/c1-15-7-2-4-8(5-3-7)16(13,14)10-6-9(11)12/h2-5,10H,6H2,1H3,(H,11,12)/p-1

Upstream product

• 1129-26-6 4-methoxybenzene sulfonamide 
• 3926-62-3 sodium monochloroacetic acid 
• 86674-19-3 C₉H₁₀N₂O₇S 
• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 
• 56-40-6 glycine 
• 154853-46-0 2,4-dinitrophenyl 4-methoxybenzenesulfonate 
• 1388830-18-9 C₂₈H₃₅N₃O₉S 

Downstream Products

• 83800-71-9 1-(4-Methoxy-benzenesulfonyl)-2-thioxo-imidazolidin-4-one 
• 1027833-26-6 C₁₄H₁₉NO₇S 
• 83800-79-7 1-(4-Methoxy-benzenesulfonyl)-imidazolidine-2,4-dione 

Relevant articles and documents

Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds

Targeting the protein-protein interaction (PPI) between nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) is a potential therapeutic strategy to control diseases involving oxidative stress. Here, six classes of known small-molecule Keap1-Nrf2 PPI inhibitors were dissected into 77 fragments in a fragment-based deconstruction reconstruction (FBDR) study and tested in four orthogonal assays. This gave 17 fragment hits of which six were shown by X-ray crystallography to bind in the Keap1 Kelch binding pocket. Two hits were merged into compound 8 with a 220-380-fold stronger affinity (Ki = 16 μM) relative to the parent fragments. Systematic optimization resulted in several novel analogues with Ki values of 0.04-0.5 μM, binding modes determined by X-ray crystallography, and enhanced microsomal stability. This demonstrates how FBDR can be used to find new fragment hits, elucidate important ligand-protein interactions, and identify new potent inhibitors of the Keap1-Nrf2 PPI.

Design, synthesis and in vitro evaluation studies of sulfonyl-amino-acetamides as small molecule BACE-1 inhibitors

The identification of a series of sulfonyl-amino-acetamides as BACE-1 (β-secretase) inhibitors for the treatment of Alzheimer's disease is reported. The derivatives were designed based on the docking simulation study, synthesized and assessed for BACE-1 inhibition in vitro. The designed ligands revealed desired binding interactions with the catalytic aspartate dyad and occupance of S1 and S2′ active site regions. These in silico results correlated well with in vitro activity. Out of 33 compounds synthesized, 12 compounds showed significant inhibition at 10 μM concentration. The most active compound 2.17S had IC50 of 7.90 μM against BACE-1, which was concomitant with results of in silico docking study.

Design and synthesis of procollagen C-proteinase inhibitors

Non-peptidic inhibitors of procollagen C-proteinase (PCP) were designed from substrate leads. Compounds were optimized for potency and selectivity, with N-substituted aryl sulfonamide hydroxamates having the best combination of these properties. Compounds